The Company welcomes new development partnerships and collaborations with both industry and academia for its proprietary oral T-cell activation therapy platform and product candidates. VAXIMM works with leading academic institutions and pharmaceutical companies in its development activities.

For more information, please contact us.
Please read the Terms of Use and Privacy Policy and confirm your acknowledgement by ticking the box:
Then you will be automatically forwarded to our e-mail form.